ClinicalTrials.gg
RecruitingNCT07555119N2N-OSAUpdated Jul 29, 2026

Night-to-Night Variability of Novel Physiological Parameters in Home Sleep Apnea Testing

An observational study in Obstructive Apnea, Diagnostic and Sleep Apnea Syndrome (OSAS), sponsored by Insel Gruppe AG, University Hospital Bern. Recruiting at 1 site in Switzerland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-29.

Sponsored by Insel Gruppe AG, University Hospital Bern · Observational

How we know

From the registry’s dates

  • Started Jul 2026; still recruiting 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
192
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 53 studies in Sleep Apnea, Obstructive with a site in Switzerland — 6 open to participants now, 8 under way, none of them phase 3. Sleep Apnea, Obstructive · Switzerland.

Planned enrollment
10th of 22
192 · median 162
Started
2026
the only one that year
Observational
22 of 53
4 open now
Registered
53rd of 53
by date
Lead sponsor
3 of 53
Insel Gruppe AG, University Hospital Bern

Among the 53 studies in Sleep Apnea, Obstructive with a site in Switzerland, this one is the 10th largest by planned enrollment of the 22 observational ones that give a count, is the only one that started in 2026, is one of 22 observational ones, and was the 53rd registered.

Sleep Apnea, Obstructive

2,246 studies on the registry are indexed under Sleep Apnea, Obstructive; 476 are open to participants now.

Browse Sleep Apnea, Obstructive studies →

Open to participants now

6 of the 53 studies in Sleep Apnea, Obstructive with a site in Switzerland are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in Switzerland have not opened yet or have stopped. Only those recruiting at a site in Switzerland →

Who these studies take

Of the 317 Sleep Apnea, Obstructive studies recruiting now, 149 (47%) set no upper age limit and 124 (39%) stop at 75 or younger; 53 take children under 18; 66 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 53 studies in Sleep Apnea, Obstructive with a site in Switzerland, or all of them as a file.
02

Study summary

Obstructive sleep apnea (OSA) is usually diagnosed from a single night of home sleep apnea testing using the apnea-hypopnea index (AHI). However, the AHI varies substantially from night to night, undermining diagnostic accuracy, and shows only modest correlation with symptoms. This variability further limits its usefulness for predicting cardiovascular and other complications. Besides the traditional AHI, more robust physiological markers are needed.

Several emerging physiological metrics - hypoxic burden, ventilatory burden, heart rate variability, autonomic arousals, and the pulse wave amplitude drop index - capture the physiological impact of OSA more comprehensively and demonstrate stronger associations with cardiovascular risk. Despite this promise, their night-to-night variability has not been studied.

A systematic evaluation of both established and novel OSA metrics across nights is essential to identify reliable, stable parameters suitable for clinical routine. This improves diagnostic precision beyond what traditional metrics can provide, enhances patient selection, reduces costs and patient harm, and may improve treatment outcomes.

03

Conditions studied

  • Obstructive Apnea
  • Diagnostic
  • Sleep Apnea Syndrome (OSAS)

Keywords

  • Home Sleep Apnea Testing
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Participants with suspected or diagnosed sleep-disordered breathing of any severity will be recruited at Inselspital University Hospital und University Bern.

No selection or stratification based on sex, gender, or any other patient characteristics is applied during recruitment. Participants are included consecutively based on the clinical indication for home sleep apnea testing, irrespective of sex or gender. Any resulting imbalance reflects the underlying clinical population and does not compromise the scientific validity of the study, as analyses will account for sex and gender as covariates and report their effects transparently.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with suspected or diagnosed sleep-disordered breathing, irrespective of disease severity, as defined by the indications for home sleep apnea testing in the German guidelines [15]
  • No active treatment during sleep recordings or within preceding two weeks (e.g., mandibular advancement devices, positive airway pressure therapy)
  • Written obtained

Exclusion criteria

Exclusion Criteria:

  • Age \<18 years
  • Known or suspected neurological sleep disorder (e.g., narcolepsy, parasomnia)
  • Known or suspected psychiatric sleep disorder
  • Known or suspected central and complex sleep apnea
  • Participants who are unable to perform sleep measurements reliably
  • Insufficient knowledge of the project language (German)
  • Inability to give consent
  • Shift workers (with shift work \<2 weeks before testing)
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
192 participants (estimated)
Patient registry
No

Groups and cohorts

  • All participants

    Participants will undergo repeated sleep testing using respiratory polygraphy over 4 nights and oximetry over 10 nights, starting in parallel. Before and after the recordings they will fill out symptom questionnaires and patient-reported outcome measures.

06

What researchers measure

Primary outcomes

  1. Night-to-night variability of apnea-hypopnea index (events per hour of sleep) over 4 nights

    The variability of the apnea-hypopnea index (events per hour of sleep) over 4 nights will be quantified using linear mixed-effects models, accounting for confounding variables.

    Time frame: 4 nights of respiratory polygraphy

  2. Night-to-night variability of oxygen desaturation index (events per hour of sleep) over 10 nights

    The variability will be quantified using linear mixed-effects models, accounting for confounding variables.

    Time frame: 4 nights of respiratory polygraphy and 10 nights of oxymetry

  3. Night-to-night variability of hypoxic burden (minute x percent per hour of sleep) over 10 nights

    The variability will be quantified using linear mixed-effects models, accounting for confounding variables.

    Time frame: 4 nights of respiratory polygraphy and 10 nights of oxymetry

  4. Night-to-night variability of ventilatory burden over 4 nights

    The variability will be quantified using linear mixed-effects models, accounting for confounding variables. Ventilatory burden will be calculated according to Parekh et al.

    Time frame: 4 nights of respiratory polygraphy

  5. Night-to-night variability of heart rate variability over 10 nights

    The variability will be quantified using linear mixed-effects models, accounting for confounding variables.

    Time frame: 4 nights of respiratory polygraphy and 10 nights of oxymetry

  6. Night-to-night variability of pulse wave amplitude drops (events per hour) over 10 nights

    The variability will be quantified using linear mixed-effects models, accounting for confounding variables.

    Time frame: 4 nights of respiratory polygraphy and 10 nights of oxymetry

Secondary outcomes

  1. Identification of factors contributing to and explaining variability

    Each influencing factor will be evaluated on its potential to explain the observed variability in the objective physiological parameters listed above. Each factor will be included individually as a fixed effect in the mixed-effects model and tested for significance. The following factors will be analyzed: * Age (years) * Body mass index (kg(m2) * Gender * Upper airway anatomy (tonsil size) * Mean OSA severity over all nights (of the respective parameter) * Sleep position (supine time as a percent of sleep time) * Alcohol consumption (number of drinks) * Caffeine intake (number of cups) * Nicotine use (number of packages) * Sleep Medication (free text) * Subjective sleep quality (visual analog scale, VAS, 0 to 10 points) * Snoring intensity (VAS, 0 to 10 points) * Daytime sleepiness on a VAS of the subsequent day (0 to 10 points) * Daytime sleepiness on the Epworth Sleepiness Scale of the subsequent day (0 to 24 points) * Respiratory symptoms such as infection (VAS) * Allergy symptoms

    Time frame: 4 nights of respiratory polygraphy and 10 nights of oxymetry

  2. Correlation between physiological parameters from sleep testing and patient-reported outcome measures (PROMs)

    Associations between physiological metrics and PROMs will be assessed using mixed-effects models, analogously to the analysis of influencing factors above and correlation analysis (Spearman's rank coefficient). Patient-reported symptoms for correlation analyses: * Sleep quality on a VAS (0 to 10 points) * Snoring intensity on a VAS (0 to 10 points) * Daytime sleepiness on a VAS (0 to 10 points) * Epworth Sleepiness Scale (0 to 24 points)

    Time frame: 4 nights of respiratory polygraphy and 10 nights of oxymetry

07

Study locations

1 of 1 sites recruiting
  • Inselspital University Hospital and University Bern
    Bern, 3010, Switzerland
    Recruiting
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2026 (actual). Primary completion is estimated for Jun 2027, 11 months after the start.

Of 258 non-industry observational studies under Sleep Apnea, Obstructive, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 63. This study's planned 11 months is below that.

Counting every sponsor, half of 294 studies reached it within 29 months; a quarter within 14 and three quarters within 63.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 16, 2026
First posted
Apr 29, 2026
StartActual
Jul 24, 2026
Primary completionEst.
Jun 30, 2027
CompletionEst.
Jun 30, 2027
Last update
Jul 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 29, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07555119
Responsible party
Sponsor
First posted
Apr 29, 2026
Start date
Jul 24, 2026
Primary completion
Jun 30, 2027 (estimated)
Completion
Jun 30, 2027 (estimated)
Last update
Jul 29, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion